IRONWOOD PHARMACEUTICALS, INC. (IRWD) Operating Margin
- Operating margin · 12 months: Value 60.15%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 60.15% | Operating income / revenue. Period ending 2026-06-30. $234.17M ÷ $389.32M × 100 ≈ 60.15% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 234.17M USD | Operating Income (Loss) |
| Revenue | 389.32M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
| Research and development | 88.69M USD | Research and Development Expense |
| Selling, general and administration | 64.55M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $234.17M | $389.32M | (m) | $88.69M | $64.55M | 60.15% |
| 2026-03-31 | $200.18M | $361.51M | (m) | $89.64M | $70.03M | 55.37% |
| 2025-12-31 | $98.50M | $296.15M | (m) | $95.14M | $82.26M | 33.26% |
| 2025-09-30 | $123.19M | $338.99M | (m) | $98.66M | $96.55M | 36.34% |
| 2025-06-30 | $73.34M | $308.52M | (m) | $106.02M | $110.76M | 23.77% |
| 2025-03-31 | $53.00M | $317.68M | (m) | $113.04M | $130.93M | 16.68% |
| 2024-12-31 | $93.12M | $351.41M | (m) | $111.42M | $144.27M | 26.50% |
| 2024-09-30 | $99.22M | $378.42M | (m) | $121.71M | $149.35M | 26.22% |
| 2024-06-30 | $113.61M | $400.56M | (m) | $124.86M | $149.28M | 28.36% |
| 2024-03-31 | $-994.51M | $413.55M | (m) | $129.05M | $164.80M | -240.48% |
| 2023-12-31 | $-945.43M | $442.74M | (m) | $116.08M | $158.31M | -213.54% |
| 2023-09-30 | $-914.66M | $432.38M | (m) | $90.86M | $148.04M | -211.54% |
| 2023-06-30 | $-886.21M | $427.28M | (m) | $69.42M | $140.61M | -207.41% |
| 2023-03-31 | $252.59M | $417.13M | (m) | $46.29M | $118.25M | 60.55% |
| 2022-12-31 | $250.34M | $410.60M | (m) | $44.27M | $115.99M | 60.97% |
| 2022-09-30 | $238.57M | $420.53M | (m) | $65.67M | $116.29M | 56.73% |
| 2022-06-30 | $235.26M | $415.64M | (m) | $65.03M | $115.41M | 56.60% |
| 2022-03-31 | $244.71M | $422.44M | (m) | $65.74M | $112.34M | 57.93% |
| 2021-12-31 | $232.26M | $413.75M | (m) | $70.41M | $111.13M | 56.13% |
| 2021-09-30 | $227.05M | $413.30M | (m) | $54.82M | $116.43M | 54.94% |
| 2021-06-30 | $207.50M | $413.02M | (m) | $65.61M | $123.61M | 50.24% |
| 2021-03-31 | $175.11M | $398.43M | (m) | $75.52M | $131.21M | 43.95% |
| 2020-12-31 | $142.94M | $389.52M | $3.14M | $88.06M | $140.00M | 36.70% |
| 2020-09-30 | $141.15M | $399.14M | $13.25M | $98.33M | $145.21M | 35.36% |
| 2020-06-30 | $161.42M | $426.84M | $13.76M | $104.19M | $151.20M | 37.82% |
| 2020-03-31 | $150.28M | $439.63M | $25.07M | $110.87M | $159.81M | 34.18% |
| 2019-12-31 | $120.12M | $428.41M | $23.88M | $115.04M | $172.45M | 28.04% |
| 2019-09-30 | $12.17M | $432.80M | $34.33M | $182.19M | $205.30M | 2.81% |
| 2019-06-30 | $-200.29M | $367.32M | $38.44M | $183.80M | $214.92M | -54.53% |
| 2019-03-31 | $-257.40M | $346.21M | $31.19M | $183.99M | $246.53M | -74.35% |
| 2018-12-31 | $-238.89M | $346.64M | $32.75M | $166.50M | $241.29M | -68.92% |
| 2018-09-30 | $-222.12M | $310.15M | (m) | $162.35M | $241.06M | -71.62% |
| 2018-06-30 | $-72.46M | $331.29M | (m) | $152.62M | $247.59M | -21.87% |
| 2018-03-31 | $-73.55M | $315.26M | (m) | $151.03M | $239.44M | -23.33% |
| 2017-12-31 | $-77.39M | $298.28M | (m) | $148.23M | $233.12M | -25.94% |
| 2017-09-30 | $-106.45M | $291.53M | (m) | $146.55M | $230.38M | -36.51% |
| 2017-06-30 | $-115.30M | $270.81M | (m) | $147.01M | $213.59M | -42.58% |
| 2017-03-31 | $-89.61M | $260.08M | (m) | $141.35M | $192.72M | -34.45% |
| 2016-12-31 | $-51.87M | $273.96M | (m) | $139.49M | $173.28M | -18.93% |
| 2016-09-30 | $-51.40M | $239.81M | (m) | $128.68M | $149.58M | -21.43% |
| 2016-06-30 | $-49.30M | $213.27M | (m) | $116.98M | $135.03M | -23.11% |
| 2016-03-31 | $-75.99M | $186.66M | (m) | $113.95M | $131.07M | -40.71% |
| 2015-12-31 | $-102.09M | $149.56M | (m) | $108.75M | $125.25M | -68.26% |
| 2015-09-30 | $-129.39M | $134.32M | (m) | $108.60M | $124.31M | -96.33% |
| 2015-06-30 | $-139.94M | $111.67M | (m) | $107.89M | $122.41M | -125.32% |
| 2015-03-31 | $-153.05M | $90.76M | (m) | $101.39M | $118.75M | -168.63% |
| 2014-12-31 | $-169.37M | $76.44M | (m) | $101.89M | $118.33M | -221.58% |
| 2014-09-30 | $-182.98M | $43.39M | (m) | $96.92M | $116.48M | -421.68% |
| 2014-06-30 | $-202.79M | $31.41M | (m) | $94.82M | $118.21M | -645.68% |
| 2014-03-31 | $-207.56M | $34.23M | (m) | $96.77M | $119.78M | -606.34% |
| 2013-12-31 | $-252.00M | $22.88M | (m) | $102.38M | $123.23M | -1101.36% |
| 2013-09-30 | $-249.16M | $44.83M | (m) | $108.14M | $127.78M | -555.80% |
| 2013-06-30 | $-145.00M | $136.31M | (m) | $108.57M | $120.36M | -106.38% |
| 2013-03-31 | $-125.96M | $141.25M | (m) | $116.72M | $109.59M | -89.17% |
| 2012-12-31 | $-72.76M | $150.25M | (m) | $113.47M | $92.54M | -48.43% |
| 2012-09-30 | $-35.89M | $155.42M | (m) | $109.42M | (m) | -23.09% |
| 2012-06-30 | $-105.12M | $71.22M | (m) | $108.88M | (m) | -147.59% |
| 2012-03-31 | $-83.24M | $67.88M | (m) | $96.05M | (m) | -122.62% |
| 2011-12-31 | $-66.14M | $65.87M | (m) | $86.09M | (m) | -100.41% |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | $45.26M | (m) | (m) | (m) | (m) |
| 2010-12-31 | $-60.77M | $43.86M | (m) | $77.45M | (m) | -138.55% |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $-60.82M | $34.32M | (m) | $76.10M | (m) | -177.20% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |